05:58 PM EDT, 09/24/2025 (MT Newswires) -- PepGen ( PEPG ) on Wednesday reported the highest mean splicing correction to date in patients with myotonic dystrophy type 1, an inherited disorder that causes progressive muscle weakness and stiffness.

The company said all patients in its phase 1 trial showed an improvement, with a mean correction of 53.7% observed in the latest 15 mg/kg dose group.

Separately, PepGen ( PEPG ) said it launched a public offering of common stock and pre-funded warrants. It said proceeds will support ongoing research and clinical development, including its Freedom-DM1 and Freedom2-DM1 studies, as well as working capital and general corporate purposes.

Shares of PepGen ( PEPG ) surged 92% in after-hours trading.